Abstract
The expression of CYP27B1 or vitamin D 1α-hydroxylase (1α-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1α,25-dihydroxyvitamin D [1α,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues.
Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression.
In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa.
The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa.
Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
Keywords: Vitamin D3, 24-hydroxylase, splicing variants, MCF-7, MCF-10, breast tissue.
Anti-Cancer Agents in Medicinal Chemistry
Title:Implication of CYP24A1 Splicing in Breast Cancer
Volume: 14 Issue: 1
Author(s): Chimi Scheible, Marc Thill, Sascha Baum, Erich Solomayer and Michael Friedrich
Affiliation:
Keywords: Vitamin D3, 24-hydroxylase, splicing variants, MCF-7, MCF-10, breast tissue.
Abstract: The expression of CYP27B1 or vitamin D 1α-hydroxylase (1α-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1α,25-dihydroxyvitamin D [1α,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues.
Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression.
In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa.
The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa.
Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
Export Options
About this article
Cite this article as:
Scheible Chimi, Thill Marc, Baum Sascha, Solomayer Erich and Friedrich Michael, Implication of CYP24A1 Splicing in Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/18715206113139990311
DOI https://dx.doi.org/10.2174/18715206113139990311 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Research Development of End Traction Shoulder Rehabilitation Device
Recent Patents on Mechanical Engineering Exploration of (hetero)aryl Derived Thienylchalcones for Antiviral and Anticancer Activities
Medicinal Chemistry MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy
Current Pharmaceutical Design A Review on Designing Poly (Lactic-co-glycolic Acid) Nanoparticles as Drug Delivery Systems
Pharmaceutical Nanotechnology Review: Metabolism of Immunosuppressant Drugs
Current Drug Metabolism Correlation between Cancer Antigen 15.3 Value and Qualitative and Semiquantitative Parameters of Positron Emission Tomography/Computed Tomography in Breast Cancer Patients
Current Radiopharmaceuticals Chalcones Derivatives Acting as Cell Cycle Blockers: Potential Anti Cancer Drugs?
Current Drug Targets γ-Hydroxybutenolide Containing Marine Natural Products and Their Synthesis: A Review
Current Organic Chemistry Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry Antimicrobial Activity of Royal Jelly
Anti-Infective Agents Editorial [Hot Topic:Toward Translational Research on VIP AND PACAP (Executive Editor: A. Arimura)]
Current Pharmaceutical Design Advanced Neoplastic Disease as Immunologic, Endocrine and Metabolic Disorder
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chemistry and Biology of Curacin A
Current Pharmaceutical Design Pro-inflammatory Cytokines Modulate Glial Apolipoprotein E Secretion
Current Alzheimer Research The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry Spherical Self-Organizing Map Detects MYBL 1 As Candidate Gene for Triple-Negative Breast Cancer
Neuroscience and Biomedical Engineering (Discontinued) <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer
Current Pharmaceutical Design Translocator Protein (TSPO) in Breast Cancer
Current Molecular Medicine N-Heterocyclic Dronic Acids: Applications and Synthesis
Mini-Reviews in Medicinal Chemistry